8-K: Sera Prognostics Reports Q4/FY25 Results, Extends Runway

Sera Prognostics announced its fourth quarter and full year 2025 financial results, highlighting the landmark PRIME Study publication and extended cash runway through 2028.

Summary

• Fourth quarter 2025 revenue was $10,000, compared to $24,000 for the fourth quarter of 2024.
• Full year 2025 revenue was $81,000, compared to $77,000 for full year 2024.
• Net loss for Q4 2025 was $7.9 million, an improvement from $8.6 million for Q4 2024.
• Net loss for full year 2025 was $31.9 million, an improvement from $32.9 million for full year 2024.
• As of December 31, 2025, the company had approximately $95.8 million in cash, cash equivalents, and available-for-sale securities, expected to fund operations through 2028.
• The landmark PRIME Study, a randomized controlled trial of 5,018 women, was published in January 2026, demonstrating the PreTRM blood test reduces earliest preterm births (56% before 32 weeks, 32% before 35 weeks), 20% fewer NICU admissions, and 20% reduction in neonatal morbidity.
• Sera completed a follow-on financing in February 2025, generating approximately $57.5 million in gross proceeds.
• Expanded commercial engagement across Wave 1 and Wave 2 target states, representing nearly half of U.S. pregnancies, with advanced discussions underway with 10 commercial and Medicaid payers across 13 states.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, primarily driven by the pivotal PRIME Study publication and the extended cash runway, which significantly de-risk the company's commercialization efforts despite ongoing net losses.

Positives

• The landmark PRIME Study, published in January 2026, demonstrated significant clinical benefits: 56% fewer babies born before 32 weeks, 32% fewer before 35 weeks, 20% fewer NICU admissions, and a 20% reduction in neonatal morbidity.
• A successful follow-on financing in February 2025 generated approximately $57.5 million in gross proceeds, extending the cash runway through 2028.
• Net loss improved in Q4 2025 to $7.9 million from $8.6 million in Q4 2024, and for full year 2025 to $31.9 million from $32.9 million in FY 2024.
• Total operating expenses remained stable year-over-year, decreasing slightly from $36.7 million in 2024 to $36.6 million in 2025, indicating effective capital management.
• Expanded commercial engagement and advanced discussions with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption.
• Regulatory progress is underway toward CE marking for the PreTRM Global Test in European markets, supported by growing clinical validation and expert commentary.
• Strengthened leadership team and Board of Directors with strategic appointments in 2025.

Negatives

• Fourth quarter 2025 revenue decreased to $10,000 from $24,000 in Q4 2024.
• Selling, general and administrative expenses for full year 2025 increased to $23.3 million from $21.9 million in 2024, reflecting investment ahead of expected revenue expansion.
• The company continues to incur significant net losses, totaling $31.9 million for fiscal year 2025.
• Revenues from the PreTRM Test represent substantially all company revenues to date, indicating a lack of product diversification.

Risks

• Net losses, cash generation, and the potential need to raise more capital.
• Revenues from the PreTRM Test representing substantially all Company revenues to date.
• The need for broad scientific and market acceptance of the PreTRM Test.
• A concentrated number of material customers.
• Ability to introduce new products.
• Potential competition.
• Reliance on proprietary biobank.
• Reliance on critical suppliers.
• Estimates of total addressable market opportunity and forecasts of market growth may not be accurate.
• Potential third-party payer coverage and reimbursement challenges.
• New reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes.
• Changes in FDA regulation of laboratory-developed tests.
• Intellectual property rights protecting tests and market position.

Future Outlook

Sera Prognostics expects its current cash, cash equivalents, and available-for-sale securities of approximately $95.8 million to fund the company across significant adoption and commercial milestones through 2028. The company is focused on converting its foundation of clinical validation and commercial engagement into broader adoption, payer coverage, and measurable impact in 2026, anticipating future revenue expansion. Regulatory progress is underway for CE marking and growing clinical validation for the PreTRM Global Test in European markets.

Management Comments

• "2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution." Zhenya Lindgardt, President and CEO.
• "The publication of the landmark PRIME Study delivered strong, peer-reviewed evidence that the PreTRM Test improves outcomes and reduces costs, creating a compelling value proposition for payers." Zhenya Lindgardt, President and CEO.
• "During the year we expanded engagement across our target states, advanced active discussions with both commercial and Medicaid payers, and invested deliberately in leadership, access and infrastructure to support us as we scale." Zhenya Lindgardt, President and CEO.
• "With a strengthened balance sheet, extending our runway through 2028, we enter 2026 focused on converting this foundation into broader adoption, payer coverage, and measurable impact for the families we serve." Zhenya Lindgardt, President and CEO.

Industry Context

StockSavvy.ai notes that the publication of the PRIME Study, a randomized controlled trial, is a significant de-risking event for Sera Prognostics, providing robust clinical evidence for its PreTRM test in a market segment (preterm birth prediction) that has historically lacked effective, widely adopted solutions. The emphasis on cost reduction and improved neonatal outcomes positions Sera favorably against the backdrop of rising healthcare costs and persistent challenges in maternal-fetal medicine, as highlighted by the U.S. earning a D+ grade for preterm birth for the fourth consecutive year. The European expert commentary further validates the test's potential for broader global adoption in publicly funded healthcare systems.

Comparison to Industry Standards

• The PRIME Study's findings of 56% fewer babies born before 32 weeks and 32% fewer before 35 weeks, along with a 20% reduction in NICU admissions, represent a substantial improvement over current standard-of-care approaches which often fail to identify most women at risk for preterm delivery.
• The reported saving of "a NICU day for every 4.2 patients screened" demonstrates a clear economic benefit, which is critical for gaining traction with commercial and Medicaid payers, especially when compared to the estimated $25 billion annual healthcare costs associated with prematurity in the U.S. for 2016.
• The European expert commentary recognizing PreTRM as a scalable, cost-effective approach aligns with global healthcare trends emphasizing value-based care and prevention, potentially positioning Sera ahead of less validated or more expensive diagnostic alternatives in the European market.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to strong clinical data, extended cash runway, and commercialization efforts, but also continued net losses and reliance on a single product.
• Patients/Families: Improved health outcomes for mothers and newborns through early prediction of preterm birth risk, leading to fewer complications and NICU admissions.
• Doctors/Healthcare Providers: Access to an early, accurate, and individualized risk prediction test for spontaneous preterm birth, enabling more informed clinical decisions.
• Payers (Commercial & Medicaid): Potential for significant cost reductions in healthcare delivery by reducing preterm births and associated complications.
• Employees: Growth in commercial organization (added six field sales staff and Head of Access) indicates expansion and potential for new opportunities.

Next Steps

• Focus on converting clinical validation and commercial foundation into broader adoption and payer coverage in 2026.
• Drive measurable impact for families served.
• Continue advanced discussions with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption.
• Advance commercialization preparations for the PreTRM Global Test across European markets, including regulatory progress toward CE marking.
• Host a conference call and live webcast on March 18, 2026, at 5:00 p.m. Eastern Time to discuss results and operational highlights.

Key Dates

Recommendation

The publication of the landmark PRIME Study, a randomized controlled trial, provides robust, peer-reviewed evidence of the PreTRM Test's efficacy in reducing preterm births and associated complications, a critical milestone for commercial adoption. This strong clinical validation, combined with the successful follow-on financing extending the cash runway through 2028, significantly de-risks the company's path to market penetration and profitability. While the company is still incurring net losses, the improved financial metrics (reduced net loss, stable operating expenses) and strategic investments in commercial infrastructure and leadership position Sera Prognostics for substantial growth as it converts clinical success into broader payer coverage and market adoption. The potential for significant cost savings for healthcare systems further strengthens its value proposition.

Keywords

Sera Prognostics, SERA, PreTRM Test, preterm birth, maternal health, neonatal health, biomarker, diagnostics, SEC filing, financial results, Q4 2025, FY 2025, PRIME Study, clinical trial, payer coverage, commercialization, equity financing, cash runway